Due to the disappointing results of mTOR inhibitor monotherapy and guided by preclinical observations that tumor cell growth of breast and prostate cancer cell lines in vitro was abrogated when treated with combination mTOR/MAP-kinase inhibition, several early-phase clinical trials examined combination therapy with mTOR inhibition (107, 117, 185, 186). This evidence concerns the gene MTOR and prostate carcinoma.